AKT1 and hepatocellular carcinoma: In addition, studies indicate that lncRNA PTENP1 suppresses the oncogenic PI3K/AKT pathway in hepatocellular carcinomas, and can be used to treat hepatocellular carcinomas via miRNAs such as miR-17, miR-19b, and miR-20 [25].